Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Other Working Capital Changes (2020 - 2025)

Historic Other Working Capital Changes for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to -$8.0 million.

  • Tarsus Pharmaceuticals' Other Working Capital Changes fell 79434.29% to -$8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.2 million, marking a year-over-year increase of 110314.09%. This contributed to the annual value of $7.0 million for FY2024, which is 14295.6% up from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its Other Working Capital Changes stood at -$8.0 million for Q3 2025, which was down 79434.29% from $23.2 million recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Other Working Capital Changes peaked at $23.2 million during Q2 2025, and registered a low of -$8.7 million during Q1 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' median Other Working Capital Changes value was $492000.0 (recorded in 2023), while the average stood at $1.0 million.
  • Over the last 5 years, Tarsus Pharmaceuticals' Other Working Capital Changes had its largest YoY gain of 312138.2% in 2025, and its largest YoY loss of 79434.29% in 2025.
  • Tarsus Pharmaceuticals' Other Working Capital Changes (Quarter) stood at $1.4 million in 2021, then decreased by 7.83% to $1.3 million in 2022, then surged by 46.31% to $1.9 million in 2023, then surged by 313.86% to $7.7 million in 2024, then crashed by 203.58% to -$8.0 million in 2025.
  • Its last three reported values are -$8.0 million in Q3 2025, $23.2 million for Q2 2025, and -$8.7 million during Q1 2025.